ArticleBMC pulmonary medicine2026
A phase therapy regimen containing clofazimine manifested high efficacy in treating Mycobacterium abscessus pulmonary disease.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe guidelines for Mycobacterium abscessus pulmonary disease do not provide a clear approach to combination therapy. This study aims to assess the effectiveness of phase therapy (PT) containing clofazimine (CFZ) for patients with Mycobacterium abscessus pulmonary disease.
methodsThis study was carried out at Beijing Chest Hospital, Capital Medical University. It included 24 confirmed cases of Mycobacterium abscessus pulmonary disease who were prospectively enrolled and treated with a CFZ-containing regimen. Additionally, 35 confirmed cases were retrospectively included for comparison. Baseline information of patients was collected. Patients were followed up for over a year. Minimal inhibitory concentration (MIC) testing was conducted on clinical isolates from patients to determine if there is a correlation between MIC values and sputum culture conversion.
resultsThe retrospective patients achieved a 36.7% (11/30) sputum culture conversion while PT achieved a 70.8% (17/24) sputum culture conversion. Patients using the PT regimen were more likely to achieve sputum culture conversion (P = 0.013). The MIC range of CFZ of baseline isolates from 54 Mycobacterium abscessus pulmonary disease patients was 0.125 -1 mg/L. Among prospective patients, the success rate of treatment was 86.7% (13/15) for patients with CFZ MIC < 0.5 mg/L, while it was 44.4% (4/9) for those with MIC ≥ 0.5 mg/L. Prospective patients with CFZ MIC < 0.5 mg/L were more likely to achieve sputum culture conversion (P = 0.014). Logistic regression analysis showed that prospective patients who received the five-drug regimen were independently associated with sputum culture conversion [OR = 6.203, 95% CI = (1.171–32.865), P = 0.032).
conclusionThe PT regimen is effective against Mycobacterium abscessus pulmonary disease, particularly in cases where CFZ MIC is < 0.5 mg/L.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.